Vaxart's (NASDAQ:VXRT) shares rose following the positive results from an early stage trial of its new oral pill vaccine for ...

Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill ...

USA-based biotech Vaxart has reported positive top-line results from a Phase I trial comparing its second-generation oral ...

Vaxart (NASDAQ:VXRT) stock jumped 37.9% premarket after the company reported positive early-stage data for its ...

SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its ...

Vaxart, Inc. announced that it has obtained approval from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to begin dosing ...

Vaxart Inc (NASDAQ:VXRT) shares are trading higher in Monday’s after-hours session after the company provided business and cash runway updates. What Happened: Vaxart, a clinical-stage ...

Investors may submit written questions in advance of the conference call to ir@vaxart.com. A replay of the webcast will be available on the Company’s website at www.vaxart.com following the ...

Data show that Vaxart’s HPV vaccine constructs stimulate specific T cell immune responses, reduce tumor size, and increase survival in an animal model of human papillomavirus (HPV)-related ...

Investing.com -- Vaxart Inc (NASDAQ: VXRT) stock surged 70% after the clinical-stage biotechnology company reported positive topline results from its Phase 1 trial evaluating second-generation ...

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using ...

Vaxart says it has extended its cash runway into 2026. Vaxart plans to use recently awarded funds to conduct a Phase 2b study evaluating its oral COVID-19 vaccine candidate. Get access to the ...